NCT07216508Enrolling by invitation
Liver Transplant CGM
Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 9 Oct 2025
- Start date
- 13 Oct 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Type 2 diabetes
- NCT number
- NCT07216508
What you commit to
- Study type: Observational
- Planned participants: 40
- From 13 Oct 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- if discharge is anticipated to be \>30 days post-transplant, or
- if recent transplant also included a kidney or pancreas transplant
Other
- having a planned discharge to a rehabilitation or nursing facility,
- a contraindication to sensor placement,
Who the study is looking for
- inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mount Sinai Hospital Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.